# Evolent Health, Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [Evolent Health, Inc.](/companies/evh.md) (CIK 1628908)
- Form: 10-Q
- Filed: 2022-11-03
- Accepted by EDGAR: Nov 3, 2022, 16:28 ET
- Period: 2022-09-30
- Accession: 0001628908-22-000141
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1628908/000162890822000141/evh-20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1628908/000162890822000141/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $352.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $969.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2022-07-01 to 2022-09-30 | $3.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-01-01 to 2022-09-30 | $11.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2022-07-01 to 2022-09-30 | $68.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2022-01-01 to 2022-09-30 | $186.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-07-01 to 2022-09-30 | $13.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | $5.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-07-01 to 2022-09-30 | $4.8m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2022-01-01 to 2022-09-30 | $9.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | −$45.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | −$44.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | $2.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | −$7.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | $0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 99,308,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 91,643,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | −$47.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2022-09-30 | $156.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $393.8m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $1.76bn | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $382.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $903.0m | us-gaap:Liabilities |
| Long-term debt | at 2022-09-30 | $412.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2022-09-30 | $856.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 59,962 characters.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand the Company’s financial condition and results of operations. The MD&A is provided as a supplement to, and should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements presented in “Part I – Item 1. Financial Statements” of this Form 10-Q; our 2021 Form 10-K, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; and our current reports on Form 8-K filed in 2022.

### INTRODUCTION

### Background

Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

### Business Overview

We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models. We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology.

We were an early innovator in value-based care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company.

We manage our operations and allocate resources across two reportable segments: Evolent Health Services and Clinical Solutions. The Company’s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management. Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis. We go to market for our Specialty Care Management under the brand name New Century Health, and for our Total Cost of Care solution under the brand name Evolent Care Partners.

All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.

We have incurred operating losses since our inception, in part because we have invested heavily in resources to support our growth. We intend to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities.

### Recent Events

### Evolent Health’s Response to COVID-19

Due to the nature of the services we provide and market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition, the results of operations, or our outlook. As of September 30, 2022, we had cash and cash equivalents of $156.8 million and as of the date the financial statements were available to be issued, we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months.

The COVID-19 pandemic has also affected global access to capital and caused significant volatility in financial markets. In addition, we have and are experiencing varying levels of inflation resulting in part from higher labor costs. Significant deterioration of the U.S. and global economies or rapid increases in inflation could have an adverse impact on our future liquidity needs. Although the impact of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on medical costs (including in oncology and cardiology), our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants such as Omicron and the effectiveness of vaccines. A prolonged economic downturn or recession resulting from the pandemic or more broadly, including from macroeconomic conditions could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.

Evolent’s focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish uninterrupted high-quality service to our partners. Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel, Chief Compliance Officer and Chief People and Brand Officer, that focuses on maintaining its workforce in a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities. Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors and we will continue to work with them regarding our collective obligations to Evolent’s customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner.

Evolent has instituted a voluntary return to the office. Fully vaccinated employees and those who have provided an approved religious or medical exemption are permitted to return to the Company’s offices in-person.

#### Summary of Impact of COVID-19

In evaluating the impact of COVID-19 on our business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends. In addition, we focused on possible changes in membership and medical utilization trends. Based on our analysis, we do not believe that our overall membership has been significantly impacted by the pandemic to date. With regards to medical utilization trends, in particular in our two largest specialties oncology and cardiology, while forecasting future impact is challenging, our analysis suggests that utilization during the nine months ended September 30, 2022 (as measured by authorizations per thousand members) is similar to what it was before the pandemic.

Our two most significant service offerings in terms of revenue are specialty care management and administrative simplification services. Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic.

### Impact of Inflation

We experience pricing pressures in the form of competitive prices in addition to rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits and facility leases. We do not believe these impacts were material to our revenues or net income during the nine months ended September 30, 2022. However, significant sustained inflation driven by the macroeconomic environment or other factors could negatively impact our margins, profitability and results of operations in future periods.

### Customers

The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:

|  | For the Three Months Ended September 30, 2022 | 2021 | For the Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Cook County Health and Hospitals Systems | 21.2% | 29.0% | 23.0% | 29.0% |
| Florida Blue Medicare, Inc. | 13.7% | 13.8% | 12.5% | 14.2% |

### Transactions

The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.

#### Acquisition of IPG

On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners.

Total merger consideration, net of cash on hand and certain closing adjustments, was $461.7 million, based on the closing price of the Company’s Class A common stock on the NYSE on August 1, 2022. The merger consideration consisted of $256.5 million of cash consideration, 3.7 million shares of Class A common stock, fair valued at $130.2 million as of August 1, 2022, and an earn-out of up to $87.0 million, fair valued at $75.0 million as of August 1, 2022 is payable in cash and/or shares of the Company’s Class A Common Stock, at the Company’s option. IPG will report into Evolent’s specialty care management offering, New Century Health, and will be consolidated into the Company’s Clinical Solutions segment. Refer to “Part I - Item 1. Financial Statements - Note 4” for additional discussion regarding the IPG transactions.

#### Ares Secured Credit Facilities

On August 1, 2022 (the “Closing Date”), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (“Evolent”), Endzone Merger Sub, Inc. (“Endzone” or “Initial Borrower”), which upon consummation of the transactions contemplated by the Merger Agreement was merged with and into TPG Growth Iceman Parent, Inc., Implantable Provider Group, Inc. (“Implantable”, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the “Borrowers” and each a “Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the “2022 Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of (i) an initial term loan in the aggregate principal amount of $175.0 million (the “Initial Term Loan Facility”) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0 million, to be determined by reference to the lesser of $50.0 million and a borrowing base (the “Revolving Facility” and, together with the Initial Term Loan Facility, the “2022 Credit Facilities”), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the “Initial Term Loan”), and also borrowed $50.0 million under the Revolving Facility on the Closing Date.

The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of the Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the Closing Date and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the Closing Date. Refer to “Part I - Item 1. Financial Statements - Note 10” for additional discussion regarding the 2022 Credit Facilities.

#### 2024 Notes Conversion

On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8 million in aggregate principal amount of such notes for shares of the Company’s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes resulted in a $10.2 million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).

#### Subsequent Events

On October 11, 2022, our Evolent Health Services segment was notified by Bright Health Group that it intended to exit its Individual and Family lines of business. Due to an expected decrease in projected future cash flows which could impact our estimated fair value, our existing goodwill in the EHS segment may require an adjustment. Such adjustment could be material. As of the date of this filing, the Company has not yet completed the analysis due to the complexities and time involved in determining the implied fair value of the goodwill. The analysis will be completed in the fourth quarter of 2022. As of September 30, 2022, goodwill in our EHS segment is $214.2 million. If the fair value of the EHS segment is determined to be less than the carrying value, an adjustment to goodwill will be required, and such amount could be material.

### Critical Accounting Policies and Estimates

The MD&A included in our 2021 Form 10-K contains a detailed discussion of our critical accounting policies and estimates. There have been no material changes to our critical accounting policies and estimates since our 2021 Form 10-K. See “Item 1. Financial

Statements - Note 2” in this Form 10-Q for a summary of our significant accounting policies and see “Item 1. Financial Statements - Note 3” in this Form 10-Q for information regarding the Company’s adoption of new accounting standards.

### Summary of Significant Accounting Policies

Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2021 Form 10-K for a complete summary of our significant accounting policies.

#### Goodwill

We recognize the excess of the purchase price plus the fair value of any non-controlling interests in the acquiree over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.

Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. Qualitative factors include macroeconomic, industry and market considerations, overall financial performance, industry, legal and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit’s fair value.

If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). We use discounted cash flow analyses and market multiple analyses in order to estimate reporting unit fair values. Discounted cash flow analyses rely on significant judgement and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates and operating margins. These assumptions are based on estimates of future revenue and earnings after considering such factors as general economic and market conditions which drive key assumptions of revenue growth rates, operating margins, capital expenditures and working capital requirements. The weighted average cost of capital is based on market-based factors/inputs but also considers the specific risk characteristics of the reporting unit’s cash flow forecast. A significant change to these estimates and assumptions could cause the estimated fair values of our reporting units and intangible assets to decline and increase the risk of an impairment charge to earnings. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest fair value of our single reporting unit was below the carrying value. As a result, a quantitative goodwill impairment analysis was not required.

We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the nine months ended September 30, 2022. We will perform our annual impairment test on October 31, 2022, including assessing the qualitative and quantitative indicators from the shutdown of Bright Health Group’s Individual and Family Plans line of business.

### Adoption of New Accounting Standards

In December 2019, the FASB issued ASU No. 2019-12, *Simplifying the Accounting for Income Taxes*. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard on January 1, 2022 however, it did not have a material impact on our consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, *Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity*. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU’s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity’s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. The Company adopted the standard using a modified retrospective method as of January 1, 2022, with adjustments which reduced additional paid-in capital by $106.2 million and increased retained earnings by $39.8 million and increased the net carrying amount of the 2024 Notes and 2025 Notes by $25.1 million and $41.3 million.

### RESULTS OF OPERATIONS

Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

### Key Components of our Results of Operations

#### Revenue

We derive revenue primarily from platform and operations services.

Platform and Operations Services Revenue

Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.

Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time.

In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope.

Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.

Contracts with Multiple Performance Obligations

Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.

In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.

#### Cost of Revenue (exclusive of depreciation and amortization)

Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.

#### Selling, General and Administrative Expenses

Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.

#### Depreciation and Amortization Expense

Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC’s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.

#### Lives on Platform and PMPM Fees

Total Lives on Platform are calculated by summing our Evolent Health Services Lives on Platform and our Clinical Solutions Lives on Platform. Evolent Health Services Lives on Platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform. Clinical Solutions Lives on Platform are calculated by summing the Clinical Solutions Lives on Platform in our Performance suite and New Century Health Technology and Services suite Lives on Platform. Clinical Solutions Lives on Platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Health Technology and Services suite Lives on Platform are calculated by summing members covered for oncology specialty care services, members covered for cardiology specialty care services and members covered for advance care planning services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. Clinical Solutions Cases are calculated by summing the number of individuals receiving services through our IPG and Vital Decisions programs in a given period.

Evolent Health Services average per member per month (“PMPM”) fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment during the period reported divided by the average of the beginning and ending Evolent Health Services segment membership during the period reported divided by the number of months in the period. Clinical Solutions Performance suite Average PMPM fee is defined as platform and operations services revenue pertaining to our Clinical Solutions Performance suite during the period reported divided by the average of the beginning and ending Clinical Solutions Performance suite membership during the period reported divided by the number of months in the period. New Century Health Technology and Services suite Average PMPM fee is defined as platform and operations revenue pertaining to the New Century Health Technology and Services suite during the period reported divided by the average of the beginning and ending New Century Health Technology and Services suite membership during the period reported divided by the number of months in the period. Clinical Solutions Revenue per Case is calculated by the revenue pertaining to IPG and Vital divided by the number of cases for a given period.

Management uses lives on platform, PMPM fees, cases and revenue per case because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.

### Evolent Health, Inc. Consolidated Results

*(in thousands, except percentages)*

| 2022 | For the Three Months Ended September 30, 2021 |  | Change Over Prior Period $% | 2022 | For the Nine Months Ended September 30, 2021 |  | Change Over Prior Period $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| **Revenue** | $352,585 | $222,471 | $130,114 | 58.5% | $969,581 | $659,599 | $309,982 | 47.0% |
| **Expenses** |  |  |  |  |  |  |  |  |
| Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) | 266,617 | 163,126 | 103,491 | 63.4% | 736,061 | 493,071 | 242,990 | 49.3% |
| Selling, general and administrative expenses | 68,521 | 51,292 | 17,229 | 33.6% | 186,408 | 152,582 | 33,826 | 22.2% |
| Depreciation and amortization expenses | 17,196 | 14,859 | 2,337 | 15.7% | 47,414 | 44,962 | 2,452 | 5.5% |
| Change in fair value of contingent consideration | (12,700) | (225) | (12,475) | (5,544.4)% | (5,822) | (819) | (5,003) | (610.9)% |
| Total operating expenses | 339,634 | 229,052 | 110,582 | 48.3% | 964,061 | 689,796 | 274,265 | 39.8% |
| Operating income (loss) | $12,951 | $(6,581) | $19,532 | 296.8% | $5,520 | $(30,197) | $35,717 | 118.3% |
| Cost of revenue as a % of revenue | 75.6% | 73.3% |  |  | 75.9% | 74.8% |  |  |
| Selling, general and administrative expenses as a % of revenue | 19.4% | 23.1% |  |  | 19.2% | 23.1% |  |  |

### Comparison of the Results for the Three Months Ended September 30, 2022 to 2021

#### Revenue

Total revenue increased by $130.1 million, or 58.5%, to $352.6 million for the three months ended September 30, 2022, as compared to 2021. This increase is primarily due to the addition of new partners and expansion with existing partners.

The following table represents Evolent’s revenue disaggregated by segment and end-market (in thousands):

|  | For the Three Months Ended September 30, 2022 Evolent Health Services | 2021 | 2022 Clinical Solutions | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Medicaid | $60,054 | $41,857 | $79,664 | $51,829 |
| Medicare | 6,335 | 4,816 | 111,632 | 105,219 |
| Commercial and other | 40,939 | 16,184 | 53,961 | 2,566 |
| Total | $107,328 | $62,857 | $245,257 | $159,614 |

Revenue from our Evolent Health Services segment increased by $44.5 million for the three months ended September 30, 2022, as compared to 2021 due to the addition of new partners. Revenue from our Clinical Solutions segment increased by $85.6 million for three months ended September 30, 2022 as compared to 2021 due to new partner additions as well as expansion into new markets.

The following table represents the Company’s lives on platform as of September 30, 2022 and 2021 and PMPM fees for the three months ended September 30, 2022 and 2021 (Lives on Platform in thousands):

|  | Lives on Platform/ Cases during Period September 30, 2022 | 2021 | Average PMPM Fees / Revenue per Case For the Three Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Evolent Health Services | 2,123 | 1,564 | $16.41 | $13.19 |
| Clinical Solutions |  |  |  |  |
| Performance suite | 2,498 | 1,471 | 27.02 | 34.16 |
| New Century Health Technology and Services suite | 14,853 | 11,670 | 0.29 | 0.36 |
| Cases | 13 | — | 2,201.00 | — |

We had 52 and 41 operating partners as of September 30, 2022 and 2021, respectively.

#### Cost of Revenue

The following table provides a summary of our total cost of revenue by segment (amounts in thousands):

|  | For the Three Months Ended September 30, 2022 Evolent Health Services | 2021 | 2022 Clinical Solutions | 2021 | 2022 Corporate | 2021 | 2022 Total | 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $53,635 | $42,651 | $212,377 | $119,894 | $605 | $581 | $266,617 | $163,126 |

Cost of revenue increased by $103.5 million, or 63.4%, to $266.6 million for the three months ended September 30, 2022, as compared to 2021, principally as a result of the growth in our revenue. By key line items, the increase was driven by approximately $68.6 million due to higher claims activity in our Clinical Solutions and Evolent Health Services segments, $11.7 million due to higher personnel costs due to increased headcount and benefits to employees, $15.1 million of surgical management device costs at IPG and $5.4 million in higher professional fees primarily due to costs incurred for contracts that went live during the quarter and third-party service fees for existing customers. Approximately $1.0 million and $0.1 million of total personnel costs was attributable to stock-based compensation expense for the three months ended September 30, 2022 and 2021, respectively. Cost of revenue represented 75.6% and 73.3% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.

#### Selling, General and Administrative Expenses

The following table provides a summary of our total selling, general and administrative by segment (amounts in thousands):

|  | For the Three Months Ended September 30, 2022 Evolent Health Services | 2021 | 2022 Clinical Solutions | 2021 | 2022 Corporate | 2021 | 2022 Total | 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $26,867 | $26,826 | $16,412 | $4,314 | $25,242 | $20,152 | $68,521 | $51,292 |

Selling, general, and administrative expenses increased by $17.2 million, or 33.6%, to $68.5 million for the three months ended September 30, 2022, as compared to 2021. The increase is driven primarily by the acquisitions of Vital Decisions and IPG. By key line items, the increase was driven by higher personnel fees due to increased headcount and expected benefits accruals to employees of $8.1 million, higher stock compensation of $1.7 million, higher insurance costs of $0.5 million and technology services due to higher headcount of $2.6 million. Approximately $6.0 million and $4.3 million of total personnel costs were attributable to stock-based compensation expense for the three months ended September 30, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $3.6 million and $1.2 million of total selling, general and administrative expenses for the three months ended September 30, 2022 and 2021, respectively. Selling, general and administrative expenses represented 19.4% and 23.1% of total revenue for the three months ended September 30, 2022, as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives completed in the fourth quarter of 2021.

#### Depreciation and Amortization Expenses

Depreciation and amortization expenses increased $2.3 million, or 15.7%, to $17.2 million for the three months ended September 30, 2022, as compared to 2021 due primarily to amortization of intangible assets acquired through our asset acquisitions and business combinations. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.

#### Change in Fair Value of Contingent Consideration

We recorded a (gain) loss on change in fair value of contingent consideration of $(12.7) million and $(0.2) million for the three months ended September 30, 2022 as compared to 2021. The change in fair value of contingent consideration for the three months ended September 30, 2022 is due to changes in the fair values of contingent liabilities incurred as a result of the acquisition of Vital Decisions in October 2021 and IPG in August 2022. The change in fair value of contingent consideration for the three months ended September 30, 2021 is due to liabilities incurred from entering into the warrant agreements as part of the 2019 Credit Agreement.

### Comparison of the Results for the Nine Months Ended September 30, 2022 to 2021

#### Revenue

Total revenue increased by $310.0 million, or 47.0%, to $969.6 million for the nine months ended September 30, 2022, as compared to 2021. This increase is primarily due to the addition of new partners and expansion with existing partners.

The following table represents Evolent’s revenue disaggregated by segment and end-market (in thousands):

|  | For the Nine Months Ended September 30, 2022 Evolent Health Services | 2021 | 2022 Clinical Solutions | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Medicaid | $183,542 | $154,850 | $226,684 | $148,816 |
| Medicare | 21,031 | 19,500 | 315,334 | 281,763 |
| Commercial and other | 101,948 | 48,207 | 121,042 | 6,463 |
| Total | $306,521 | $222,557 | $663,060 | $437,042 |

Revenue from our Evolent Health Services segment increased by $84.0 million for the nine months ended September 30, 2022, as compared to 2021 due to expansion of services with existing customers. Revenue from our Clinical Solutions segment increased by $226.0 million for the nine months ended September 30, 2022 as compared to 2021 due to new partner additions as well as expansion into new markets within current New Century Health Technology and Services Suite partners.

The following table represents the Company’s lives on platform as of September 30, 2022 and 2021 and PMPM fees for the nine months ended September 30, 2022 and 2021 (Lives on Platform in thousands):

|  | Lives on Platform/ Cases during Period September 30, 2022 | 2021 | Average PMPM Fees / Revenue per Case For the Nine Months Ended September 30, 2022 |  | 2021 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Evolent Health Services | 2,123 | 1,564 | $18.00 |  | $12.23 |
| Clinical Solutions |  |  |  |  |  |
| Performance suite | 2,498 | 1,471 | 32.41 |  | 28.78 |
| New Century Health Technology and Services suite | 14,853 | 11,670 | 0.30 |  | 0.38 |
| Cases | 24 | — | 1,472.40 | — | — |

47

#### Cost of Revenue

The following table provides a summary of our total cost of revenue by segment for the nine months ended September 30, 2022, as compared to 2021 (amounts in thousands):

|  | For the Nine Months Ended September 30, 2022 Evolent Health Services | 2021 | 2022 Clinical Solutions | 2021 | 2022 Corporate | 2021 | 2022 Total | 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $169,612 | $145,354 | $564,628 | $345,874 | $1,821 | $1,843 | $736,061 | $493,071 |

Cost of revenue increased by $243.0 million, or 49.3%, to $736.1 million for the nine months ended September 30, 2022, as compared to 2021, principally as a result of the growth in our revenue. By key line items, the increase was driven by approximately $164.7 million due to higher claims activity in our Clinical Solutions and Evolent Health Services segments, $32.9 million of higher personnel costs due to increased headcount, employee benefits and expected bonus accruals to employees, $22.6 million in higher professional fees primarily due to costs incurred for contracts that went live during the quarter and third-party service fees for existing customers and $15.1 million of surgical management device costs at IPG. Approximately $3.0 million and $1.6 million of total personnel costs was attributable to stock-based compensation expense for the nine months ended September 30, 2022 and 2021, respectively. Cost of revenue represented 75.9% and 74.8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.

#### Selling, General and Administrative Expenses

The following table provides a summary of our total selling, general and administrative by segment for the nine months ended September 30, 2022, as compared to 2021 (amounts in thousands):

|  | For the Nine Months Ended September 30, 2022 Evolent Health Services | 2021 | 2022 Clinical Solutions | 2021 | 2022 Corporate | 2021 | 2022 Total | 2021 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $69,264 | $69,555 | $43,398 | $21,086 | $73,746 | $61,941 | $186,408 | $152,582 |

Selling, general, and administrative expenses increased by $33.8 million, or 22.2%, to $186.4 million for the nine months ended September 30, 2022, as compared to 2021, principally as a result of acquisitions. By key line items, the increase was driven by higher personnel fees due to increased headcount and expected benefits accruals to employees of $26.1 million, higher stock compensation of $6.3 million, technology services due to higher headcount of $6.8 million and higher insurance costs of $1.0 million offset, in part by lower professional fees from the Repositioning Plan and shareholder advisory services of $9.2 million and the termination of certain leases of $2.6 million. Approximately $16.4 million and $10.1 million of total personnel costs were attributable to stock-based compensation expense for the nine months ended September 30, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $7.5 million and $3.3 million of total selling, general and administrative expenses for the nine months ended September 30, 2022 and 2021, respectively. Selling, general and administrative expenses represented 19.2% and 23.1% of total revenue for the nine months ended September 30, 2022, as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives completed in the fourth quarter of 2021.

#### Depreciation and Amortization Expenses

Depreciation and amortization expenses increased $2.5 million, or 5.5%, to $47.4 million for the nine months ended September 30, 2022, as compared to 2021 due primarily to amortization of intangible assets acquired through our asset acquisitions and business combinations. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.

#### Change in Fair Value of Contingent Consideration

We recorded a gain on change in fair value of contingent consideration of $(5.8) million for the nine months ended September 30, 2022, related to the liabilities acquired as a result of the acquisitions of Vital Decisions in October 2021 and IPG in August 2022 and $(0.8) million for the nine months ended September 30, 2021, related to liabilities incurred from entering into our warrant agreements as part of the 2019 Credit Agreement that were settled in January 2021.

### Discussion of Non-Operating Results

#### Interest Expense

Our interest expense is primarily attributable to our 2021, 2024 and 2025 Notes as well as our 2022 and 2019 Credit Agreements with Ares Capital Corporation. We recorded interest expense (including amortization of deferred financing costs) of approximately $4.8 million and $9.1 million for the three and nine months ended September 30, 2022, respectively, and $6.4 million and $19.0 million for the three and nine months ended September 30, 2021, respectively. The decrease in interest expense during the three and nine months ended September 30, 2022 compared to 2021 is driven primarily by the adoption of ASU 2020-06 and conversion of the 2024 Notes offset, in part by interest expense incurred on our 2022 Credit Agreement See “Part I - Item 1. Financial Statements - Note 10” in this Form 10-Q for the information related to interest expense.

#### Gain from Equity Method Investees

The Company allocated its proportional share of the investees’ earnings and losses each reporting period. The Company’s proportional share of the gain from these investments was approximately $1.4 million and $3.9 million for the three and nine months ended September 30, 2022, respectively, and $0.1 million and $12.7 million for the three and nine months ended September 30, 2021, respectively. The change in gain from equity method investees for the three and nine months ended September 30, 2022 compared to 2021 is driven primarily by the sale of our Florida equity investee’s membership during the three months ended March 31, 2021.

#### Gain from Transfer of Membership

In the three months ended March 31, 2021, EVH Passport received a cash payment from Molina in the amount of $23.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive based on the number of such enrollees. The remaining 50% was received in the first quarter of 2022.

#### Loss on Extinguishment/Repayment of Debt

On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8 million in aggregate principal amount of such notes for shares of the Company’s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes resulted in a $10.2 million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6 million, which included $9.7 million for the make-whole premium as well as $0.2 million in accrued interest.

As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2 million, representing the remaining unamortized debt issuance costs of $9.5 million, the make-whole premium and legal expenses.

#### Change in Tax Receivable Agreement Liability

Due to the reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $42.9 million as of September 30, 2022, which represents 85% of the deferred tax assets related to the Company’s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.

#### Provision for (Benefit from) Income Taxes

An income benefit of $(45.5) million and $(44.5) million and was recognized for the three and nine months ended September 30, 2022, respectively, which resulted in effective tax rates of 104.9% and 85.8%, respectively. An income tax expense of $0.2 million and $0.9 million for the three and nine months ended September 30, 2021, respectively, which resulted in effective tax rates of (1.8)% and (2.9)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components.

### REVIEW OF CONSOLIDATED FINANCIAL CONDITION

### Liquidity and Capital Resources

Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of $5.5 million and $30.2 million for the nine months ended September 30, 2022 and 2021, respectively. Net cash and restricted cash used in operating activities was $47.2 million and $27.9 million for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022, the Company had $156.8 million of cash and cash equivalents and $38.1 million in restricted cash and restricted investments.

We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies, which may require us o seek sources of financing.

#### Cash Flows

The following summary of cash flows (in thousands) has been derived from our financial statements included in “Part I - Item 1. Financial Statements - Consolidated Statements of Cash Flows:”

|  | For the Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Net cash and restricted cash used in operating activities | $(47,248) | $(27,909) |
| Net cash and restricted cash provided by (used in) investing activities | (254,659) | 38,582 |
| Net cash and restricted cash provided by (used in) financing activities | 142,395 | (90,446) |

Operating Activities

Cash flows used in operating activities of $47.2 million for the nine months ended September 30, 2022 were primarily due to our net loss of $7.8 million, non-cash items including depreciation and amortization expenses of $47.4 million, stock-based compensation expense of $19.4 million, deferred tax benefit of $(46.4) million, amortization of contract cost assets of $14.8 million, loss on extinguishment of debt of $10.2 million, change in fair value of contingent consideration of $(5.8) million and change in our tax receivable liability of $42.9 million. Our operating cash outflows were affected by the timing of our customer and vendor payments driven by increases in accounts receivables and reductions in reserves for claims and performance-based arrangements, accrued compensation and employee benefits and accrued liabilities contributed approximately $112.7 million to our cash outflows.

Cash flows used in operating activities of $27.9 million for the nine months ended September 30, 2021 were primarily due to our net loss of $32.0 million, a loss on the repayment and termination of our Credit Agreement of $19.2 million, a gain on the disposal of assets of $1.9 million, gain on the transfer of memberships of $23.0 million and non cash items including depreciation and amortization expenses of $45.1 million and stock-based compensation expense of $11.8 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and reductions in accrued liabilities and accrued compensation and employee benefits contributed approximately $88.0 million to our cash outflows. Those cash outflows were offset, in part by increased reserves for claims and performance-based arrangements of approximately $16.8 million.

Investing Activities

Cash flows used in investing activities of $254.7 million in the nine months ended September 30, 2022 were primarily attributable to $245.0 million paid for the acquisition of IPG, $9.2 million paid for a purchase price adjustment related to our disposal of True Health New Mexico and $27.6 million of investments in internal-use software and purchases of property and equipment offset, in part by $23.0 million from the transfer of membership and release of Passport escrow and $4.2 million from returns from our equity method investments.

Cash flows provided by investing activities of $38.6 million in the nine months ended September 30, 2021 were primarily attributable to cash flows of $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $14.2 million offset, in part by $17.7 million from investments in internal-use software and purchases of property and equipment and $3.0 million of purchases of investments.

Financing Activities

Cash flows used in financing activities of $142.4 million in the nine months ended September 30, 2022 were primarily related to $219.7 million received from our 2022 Credit Agreement offset in part by $48.3 million of cash outflows related to claims processing services on behalf of partners and $17.4 million from taxes withheld for restricted stock unit vesting.

Cash flows used in financing activities of $90.4 million in the nine months ended September 30, 2021 were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part by a $1.1 million decrease in net working capital balances held on behalf of our partners for claims processing services.

#### Cash flows from Discontinued Operations

The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the nine months ended September 30, 2021 were as follows:

|  |  |
| --- | ---: |
| Cash flows provided by operating activities | $5,002 |
| Cash flows used in investing activities | (2,494) |

51

#### Contractual Obligations

We believe that the amount of cash and cash equivalents on hand and cash flows from operations will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for 2022. Our estimated contractual obligations (in thousands) as of September 30, 2022, were as follows:

|  | 2022 | 2023-2024 | 2025-2026 | 2027+ | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Operating leases for facilities(1) | $2,756 | $98,519 | $59,271 | $40,377 | $200,923 |
| Purchase obligations related to vendor contracts | 3,594 | 4,565 | — | — | 8,159 |
| Debt interest and termination payments (2) | 1,506 | 6,875 | 2,588 | — | 10,969 |
| Debt principal repayment | — | 24,281 | 172,500 | 225,000 | 421,781 |
| Total contractual obligations | $7,856 | $134,240 | $234,359 | $265,377 | $641,832 |

(1) Operating leases for facilities includes $77.1 million and $40.3 million of leases not yet commenced for the 2023-2024 and 2025-2026 time periods, respectively.

(2) Debt interest and termination payments does not include potential interest payments on our floating rate 2022 Credit Facilities. The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. Refer to “Part I - Item 1. Financial Statements - Note 10” for additional discussion regarding the 2022 Credit Facilities.

#### Accounts Receivable, net

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the nine months ended September 30, 2022, accounts receivable, net, increased due primarily to the timing of cash receipts from existing customers combined with $34.2 million of receivables acquired as part of the IPG acquisition.

#### Restricted Cash and Restricted Investments

Restricted cash and restricted investments of $38.1 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $24.9 million, collateral for letters of credit required as security deposits for facility leases of $2.3 million, amounts held with financial institutions for risk-sharing arrangements of $10.9 million as of September 30, 2022. See “Part I - Item 1. Financial Statements - Note 2” for further details of the Company’s restricted cash balances.

#### Goodwill and Intangible Assets

We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used.

#### Uses of Capital

Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.

## Market risk

As filed, 2,648 characters.

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.

#### Interest Rate Risk

As of September 30, 2022, the Company had cash and cash equivalents and restricted cash and restricted investments of $194.8 million, which consisted of bank deposits with FDIC participating banks of $191.3 million, bank deposits in international banks of $2.0 million and investments in money market funds of $1.5 million.

Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.

As of September 30, 2022, we had $196.8 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. In addition, as of September 30, 2022, we had $175.0 million of aggregate principal amount in a secured term loan and $50.0 million of aggregate principal amount in a secured revolving credit facility, both of which are floating rate instruments based on the Secured Overnight Funding Rate (“SOFR”) and subject to fluctuations in interest rates. For every 1% increase in SOFR, Company would record additional interest expense of $2.3 million per annum.

Refer to the discussion in “Part I - Item 1. Financial Statements - Note 10” for additional information on our long-term debt.

#### Foreign Currency Exchange Risk

Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future, we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized a foreign currency translation losses of $0.3 million and $0.7 million for the three and nine months ended September 30, 2022.

## Controls and procedures

As filed, 2,916 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. The Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of September 30, 2022, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.

#### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We have not experienced any material impact to our internal controls over financial reporting despite most of our employees working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

#### Inherent Limitations of Internal Controls

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## Risk factors

As filed, 6,115 characters.

Our significant business risks are described in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). These risk factors are supplemented for the item described below. The risks and uncertainties we describe are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business or operations. Any adverse effect on our business, financial condition or operating results could result in a decline in the value of our securities and the loss of all or part of your investment.

***Increasing inflationary pressures and consumer costs may have a negative effect on our margins, profitability and results of operations.***

The broader U.S. economy has experienced higher than expected inflationary pressures during the first nine months of 2022 related to continued supply chain disruptions, labor shortages and geopolitical instability. Increasing inflationary pressures may have a negative effect on our profit margins and earnings due to associated costs increases. Additionally, we face an increasingly competitive labor market due to sustained labor shortages in part from the COVID-19 pandemic and are subject to inflationary pressures on employee wages and salaries which may increase labor costs. Failure to retain highly skilled employees due to wage inflation could have a material adverse impact on our business, results of operations or financial condition. See the risk factor captioned “*If we lose key members of our management team or employees or are unable to attract and retain the employees we need, our compensation costs will increase and our business and operating results will be adversely affected,”* in our 2021 Form 10-K. While we are unable to predict the direction of the economy or if inflation will increase or revert to normal levels, if the current inflationary trends continue for a sustained period of time, our margins, profitability and results of operations could be adversely affected.

***We are exposed to interest rate risk under the 2022 Credit Agreement, which could cause the Company’s debt service obligations to increase significantly.***

We are exposed to market risk from changes in interest rates. Both the Initial Term Loan Facility and Revolving Facility that comprise the Credit Facilities is based on the SOFR, a floating rate, subject to a minimum rate set in the Credit Agreement. The Federal Reserve has raised, and may in the future further raise, interest rates to combat the effects of recent high inflation. Any further increase in the SOFR will increase the Company’s debt service obligations, which could have a negative impact on the Company’s cash flow, financial position or operating results, including cash available for servicing the Company’s indebtedness, or result in increased borrowing costs in the future.

***Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt.***

Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

***Restrictive covenants in our 2022 Credit Agreement may interfere with our ability to access the revolving credit facility under the 2022 Credit Agreement, or to obtain new financing or to engage in other business activities.***

Our 2022 Credit Agreement imposes significant operating and financial restrictions on us. These restrictions limit our ability and/or the ability of certain of our subsidiaries to, among other things:

- incur or guarantee additional debt;
- incur certain liens;
- merge or consolidate;
- transfer or sell assets;
- make certain investments;
- pay dividends and make other distributions on, or redeem or repurchase, capital stock; and
- enter into transactions with affiliates.

In addition, we are required to comply with certain financial covenants consisting of a minimum liquidity test, and, commencing on the last day of the fiscal quarter ending September 30, 2022, a total secured leverage test. As a result of these restrictions, we will be limited as to how we conduct our business and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that the Company will be able to maintain compliance with these covenants in the future and, if it fails to do so, that it will be able to obtain waivers from the lenders and/or amend the covenants. The Company’s failure to comply with the restrictive covenants described above as well as the terms of any future indebtedness could result in an event of default, which, if not cured or waived, could result in it being required to repay these borrowings before their due date and the lenders would be entitled to foreclose on collateral. If the Company is forced to refinance these borrowings on less favorable terms or cannot refinance these borrowings, our results of operations and financial condition could be adversely affected. In addition, we may be unable to access future borrowings under our revolving facility if we are unable to satisfy the applicable conditions precedent.

Filed Nov 3, 2022.
Source: SEC EDGAR, the filing index for accession 0001628908-22-000141. Last ingested by Listed: Nov 15, 2026, 04:22 ET. No prices; not investment advice.
